United KingdomResearchers at The University of Texas at Austin developed an experimental drug called XJ-4-85 that targets cancer cells by manipulating their metabolism. Unlike traditional approaches that cut off sugar supply, this drug tricks cancer cells into consuming more sugar while blocking their ability to use fat as an alternate fuel source. This dual strategy forces cancer cells into metabolic distress, leading to cell death. The drug showed promise in laboratory tests against multiple cancers, including melanoma, leukemia, and others. The study, published in Nature Chemical Biology, suggests the drug could serve as a chemical alternative to antibody-drug conjugates (ADCs), which are limited by size and manufacturing complexity.
Bias read (Center): The article presents scientific research without political commentary. It focuses on medical innovation and biological mechanisms, which are apolitical topics. The tone remains neutral, describing findings without advocacy or ideological framing.
